Second primary malignancies following thyroid cancer: a population-based study in Taiwan

Lu, Chang; Lee, Kuan Der; Chen, Ping Tsung; Chen, Chih‐Cheng; Kuan, Feng Che; Huang, Cih-En; Chen, Miao Fen; Chen, Min Chi

doi:10.1530/eje-13-0309

Cited by 50 publications

(56 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[9] In another population-based study based on the Taiwan Cancer Registry, a significantly elevated risk of lung cancer was found after thyroid cancer was observed in women (SIR = 1.80, 95% CI: 1.37–2.34), but not in men (SIR = 1.24, 95% CI: 0.82–1.80). [10] Interestingly, a trend toward inverse association with EGFR mutation was observed in nonthyroid cancer, which is inconsistent with a previous study, which reported that EGFR mutations were frequently found in multiple primary cancers. [7] This discrepancy may be caused by the different study population.…”

Section: Discussioncontrasting

confidence: 81%

See 1 more Smart Citation

Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer

Kim

et al. 2017

Ann Thorac Med

View full text Add to dashboard Cite

BACKGROUND:The aim of this study was to investigate the association between epidermal growth factor receptor (EGFR) mutation and thyroid cancer in female patients with nonsmall-cell lung cancer (NSCLC).METHODS:In a retrospective study, we examined 835 female patients who were diagnosed with NSCLC and underwent an EGFR mutation test between June 2003 and August 2013. The associations of EGFR mutation with thyroid cancer and a family history of thyroid cancer were evaluated using logistic regression models.RESULTS:EGFR mutation was found in 378 of 835 patients. In addition to adenocarcinoma (P < 0.001), EGFR mutations were positively associated with a personal history of thyroid cancer (5.8% versus 2.6%; P = 0.020), while showing a trend toward inverse association with a personal history of nonthyroid cancer (5.8% vs. 9.0%; P = 0.086). Likewise, the incidence of EGFR mutations was associated with a family history of thyroid cancer (2.9% vs. 0.9%; P = 0.028), while showing a trend toward inverse association with a family history of nonthyroid cancer (27.8% vs. 33.7%; P = 0.066). Multivariate logistic regression showed that the incidence of EGFR mutations was different in women with thyroid or nonthyroid cancer (P = 0.035) and in women with a family history of thyroid or nonthyroid cancer (P = 0.023).CONCLUSIONS:Our data suggest that thyroid cancer and a family history of thyroid cancer are associated with EGFR-mutated NSCLC in female patients. The differences in the incidence of thyroid cancer and a family history of thyroid cancer by EGFR mutational status provide new insight into pathogenesis of this genetic change.

show abstract

Section: Discussioncontrasting

confidence: 81%

“…[1] Epidemiologic studies have reported that the risk of secondary primary lung cancer after thyroid cancer is significantly increased in women. [910] The EGFR pathway has been proposed to be important for thyroid cancer proliferation and metastasis. [111213] In laboratory studies, EGFR mutation and overexpression have been detected in thyroid cancer.…”

mentioning

confidence: 99%

Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer

Kim

et al. 2017

Ann Thorac Med

View full text Add to dashboard Cite

show abstract

“…While the general population would be projected to have an odds ratio of 1.0, thyroid cancer survivors have an increased risk of developing breast cancer (OR= 1.18 (95% CI [1.09,1.26])). This analysis included 44,879 thyroid cancer patients and 5,791 secondary breast cancers (22, 24, 29–44). …”

Section: Resultsmentioning

confidence: 99%

The Breast–Thyroid Cancer Link: A Systematic Review and Meta-analysis

Nielsen

White

Hong

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

113

116

View full text Add to dashboard Cite

Rates of thyroid cancer in women with a history of breast cancer are higher than expected. Similarly, rates of breast cancer in those with a history of thyroid cancer are increased. Explanations for these associations include detection bias, shared hormonal risk factors, treatment effect, and genetic susceptibility. With increasing numbers of breast and thyroid cancer survivors clinicians should be particularly cognizant of this association. Here we perform a systematic review and meta-analysis of the literature utilizing PubMed and Scopus search engines to identify all publications studying the incidence of breast cancer as a secondary malignancy following a diagnosis of thyroid cancer or thyroid cancer following a diagnosis of breast cancer. This demonstrated an increased risk of thyroid cancer as a secondary malignancy following breast cancer (OR=1.55, 95% CI [1.44,1.67]) and an increased risk of breast cancer as a secondary malignancy following thyroid cancer (OR= 1.32, 95% CI [1.23,1.42]). There is a clear increase in the odds of developing either thyroid or breast cancer as a secondary malignancy after diagnosis with the other. Here we review this association and current hypothesis as to the cause of this correlation.

show abstract

“…Furthermore, among select subgroups of cancer survivors, the lifetime risk of developing second primary malignancies may be as high as 33%, with many of these being lethal . Cancer survivors may be especially susceptible to developing second primary malignancies due to a variety of unique factors, including genetic syndromes, common etiologic exposures, and the late effects of chemotherapy and radiotherapy …”

Section: Introductionmentioning

confidence: 99%

“…Given the longer duration of cancer survivorship and the substantial percentage of survivors at risk of developing second primary malignancies, the incidence and mortality from second primary malignancies are likely to increase. There is ample literature describing the risk of second primary malignancies in certain site‐specific survivor groups, such as patients with testicular cancer, head and neck cancer, and thyroid cancer . However, to the best of our knowledge, less is known regarding the risk of second primary malignancies across the spectrum of cancer survivors diagnosed with other, more common malignancies.…”

Section: Introductionmentioning

confidence: 99%

Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008

Donin

Filson

Drakaki

et al. 2016

Cancer

273

256

View full text Add to dashboard Cite

BACKGROUND: In the current study, the authors attempted to describe the incidence, most common sites, and mortality of second primary malignancies among survivors of common cancers. METHODS: The authors identified patients aged ≥18 years who were diagnosed with a primary malignancy from the 10 most common cancer sites (prostate, breast, lung, colon, rectum, bladder, uterus, kidney, melanoma, and non-Hodgkin lymphoma) between 1992 and 2008 from Surveillance, Epidemiology, and End Results data. Factors associated with the incidence of second primary malignancies were explored using bivariable and multivariable models, and mortality attributable to first and second primary malignancies was examined. RESULTS: A cohort of 2,116,163 patients was identified, 170,865 of whom (8.1%) developed a second primary malignancy. Survivors of bladder cancer had the highest risk of developing a second cancer. In a multivariable model controlling for age, race, tumor grade, stage of disease, marital status, educational level, and income, a history of non-Hodgkin lymphoma (hazard ratios of 2.70 and 2.88, respectively, for men and women) and bladder cancer (hazard ratios of 1.88 and 1.66, respectively, for men and women) predicted the highest risk of developing a second cancer. For patients with 2 incident cancers, 13% died of their initial cancer, but greater than one-half (55%) died of their second primary malignancy. Lung cancer was the cause of death in 12% of patients with 2 incident cancers. CONCLUSIONS: Nearly 1 in 12 patients diagnosed with a common cancer developed a second malignancy, the most common of which was lung cancer. Greater than one-half of patients with 2 incident cancers died of their secondary malignancy. The findings from the current study may inform care strategies among cancer survivors.

show abstract

Second primary malignancies following thyroid cancer: a population-based study in Taiwan

Cited by 50 publications

References 30 publications

Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer

Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer

The Breast–Thyroid Cancer Link: A Systematic Review and Meta-analysis

Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008

Contact Info

Product

Resources

About